Terms ending in 2040
Every in-force patent on Cellectis's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,903,968 | Engineered Immune Cells Resistant to Tumor Microenvironment In force · High confidence | Cellectis | In force | High confidence | |
| US 12,209,125 | Targeted Gene Integration of NK Inhibitors Genes for Improved Immune Cells Therapy In force · High confidence | Cellectis | In force | High confidence | |
| US 12,221,478 | Targeted Gene Integration of CRS Inhibitor Genes for Improved Immune Cells Therapy In force · High confidence | Cellectis | In force | High confidence | |
| US 12,296,012 | Chimeric Antigen Receptors Targeting FLT3 In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 11,767,512 | New Sequence Specific Reagents Targeting CCR5 in Primary Hematopoietic Cells In force · High confidence | Cellectis | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Cellectis.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.